DAPAGLIFLOZIN
METFORMIN HYDROCHLORIDE
Approval overview DAPAGLIFLOZIN is listed in Drugs@FDA under application 211479 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE; ORAL - 5MG; 1GM Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2020-05-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview DAPAGLIFLOZIN is listed in Drugs@FDA under application 211479 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE; ORAL - 5MG; 1GM Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2020-05-01 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.